Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 20 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2017 Planned End Date changed from 1 Feb 2016 to 30 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History